- Advertisement -
- According to a new study, a once-weekly dose of tirzepatide can lead to significant, sustained weight loss for up to 3 years in adults with overweight or obesity who do not have diabetes.
- The findings build on earlier results from the SURMOUNT-1 trial and suggest that treatment responses may vary based on factors such as sex and the presence of obesity-related conditions.
- Researchers…

